Renewal and Device Changes in Morocco: Article 16 Explained

1. Key takeaways

Article 16 of Law No. 84-12 imposes two duties on the certificate holder: first, to evaluate continuously the clinical data of its products as scientific data evolves; second, to notify in writing any change affecting those clinical data or the content of the registration dossier of a device already on the market. The second paragraph adds that any change relating to the nature of the device requires a new registration application. The registration certificate is valid for 5 years (Article 6 of Décret No. 2-14-607), and renewal requires submission of a dossier. Read together, these rules extend the regulatory life of a registration far beyond the day the certificate is issued: the certificate is not a static permit but a file that must track the product. Companies that treat change management and renewal as separate, neglecting the first, usually discover the gap at the worst possible moment — during the renewal review. The sequence matters: a change identified and notified in writing when it occurs is a routine administrative step, while the same change discovered by the reviewer at renewal becomes a compliance finding.

2. Legal basis

3. Expert insights

Insight 1: Article 16 extends clinical evaluation from a pre-market gate to the entire life cycle. Article 15 is a one-time threshold; Article 16 requires the holder to evaluate continuously as scientific data advances. When new clinical evidence, new safety signals or new literature conclusions emerge, the holder is obliged to re-evaluate and, where appropriate, notify. A company that only revisits its clinical documentation at renewal is, on this reading, out of compliance for most of the certificate period. The duty is open-ended by design: it attaches to the state of scientific knowledge, not to internal project milestones.

Insight 2: changes fall into two tiers with different legal consequences. The first tier is a change affecting the clinical data or the content of the registration dossier — a written notification suffices. The second tier is a change to the nature of the device — a new registration application is required. The dividing line is whether the change touches the nature of the device itself, such as a fundamental change in the design principle, the main materials or the intended use. Getting this classification wrong in either direction carries cost: over-filing wastes review cycles, under-filing risks penalties.

Insight 3: failure to notify a change is an expressly listed penalty ground in Article 43. The provision covers failure to notify the competent authority under Article 16 of any change affecting the clinical data of devices placed on the market or the content of the registration dossier: Class I and Class IIA devices face fines of MAD 200,000 to 500,000; Class IIB and Class III devices face 2% to 5% of turnover (floor of MAD 500,000). Because promotional and production teams generate changes routinely, this is a penalty ground that can be triggered without any intentional violation. A supplier substitution, a software patch or a label edit made for commercial reasons can all qualify if they touch the registered dossier content, which is why the classification matrix below matters more than the penalty table itself.

Insight 4: this is a separate track from establishment declaration changes (Article 9). Article 9 governs changes to the declared elements of an establishment (re-declaration); Article 16 governs changes to the content of a product dossier (written notification or re-registration). A single reorganization can trigger both tracks at once, so change-control procedures should assess the two lines in parallel rather than sequentially. In practice the two tracks are administered by different filings against different declared elements, and confusing them is one of the most common procedural errors observed at establishments.

Insight 5: renewal is not an automatic extension. Article 6 provides for 5-year validity with renewal, and the practical estimate is that renewal requires the license-holding establishment to file a formal application with a dossier. At renewal, the company should check whether all changes under Article 16 were notified in full — undisclosed changes surface during the renewal review, at exactly the point where they are hardest to fix quietly. A documented notification history also shortens the renewal review itself, because the reviewer can trace the certificate from its original grant without reconstructing the product’s evolution from external evidence.

4. Practical recommendations

1. Build a change classification matrix. Assess common changes — materials, suppliers, software versions, instructions for use, labeling, packaging, intended use — one by one as “notify” or “re-apply”, and record the reasoning for each.
2. Run an annual clinical data review. Set an annual review node under Article 16, search new literature and new safety signals, and produce a written evaluation record.
3. Prepare the change notification template in French. Have the notification letter ready in advance so it can be submitted within the shortest time when a change occurs.
4. Start renewal 6 months ahead. Begin preparing the renewal dossier half a year before expiry, and at the same time verify the completeness of all past change notifications.
5. Link the check with establishment changes (Article 9). When the organization changes, assess both tracks at the same time.

5. Verification checklist

• □ A change classification matrix is in place (notification versus new registration application)
• □ The annual clinical data review node is set and written records exist
• □ A French template for change notification letters is ready
• □ The renewal reminder is set 6 months ahead and includes a dossier preparation list
• □ The completeness of past change notifications has been checked before renewal
• □ A linked check between Article 9 establishment changes and Article 16 product changes is in place
• □ The penalty tiers for unnotified changes under Article 43 have been assessed

Regulatory information verified as of October 30, 2026

Post-market support from GRZAN. GRZAN assists manufacturers and license-holding establishments in the Moroccan market with post-market compliance, including Article 16 change classification and written notifications, annual clinical data reviews, renewal dossier preparation, and inspection responses. If you need a change-management procedure aligned with Law 84-12, or want your past change history checked before a renewal filing, contact info@grzanglobal.com.